trixeo aerosphere 5/7.2/160 μg druckgasinhalation, suspension
astrazeneca ag - budesonidum, glycopyrronium, formoteroli fumaras dihydricus - druckgasinhalation, suspension - budesonidum 160 µg, glycopyrronii bromidum 9 µg corresp. glycopyrronium 7.2 µg, formoteroli fumaras dihydricus 5 µg, 1,2-distearoyl-sn-glycero-3-phosphocholinum, calcii chloridum dihydricum, norfluranum, ad suspensionem pro dosi. - la mpoc - synthetika
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
breztri aerosphere aérosol, dose mesurée
astrazeneca canada inc - budésonide; glycopyrronium (bromure de glycopyrronium); fumarate de formotérol dihydraté - aérosol, dose mesurée - 160mcg; 7.2mcg; 5mcg - budésonide 160mcg; glycopyrronium (bromure de glycopyrronium) 7.2mcg; fumarate de formotérol dihydraté 5mcg - antimuscarinics antispasmodics
trixeo aerosphere
astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.